TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26447461

Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration (CWI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CWI
Number of subjects: 50

Group type: COMPARATOR
Intervention: TEA
Number of subjects: 50
Study: 24351063

Group type: EXPERIMENTAL
Intervention: Diet and physical activity intervention
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Telephone reminders and shorter participant information leaflet
Number of subjects: 316
Study: 21316442

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 71
Study: 20037103

Group type: EXPERIMENTAL
Intervention: Single aortic clamp (SC group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional multiple aortic side‐clamp technique (MC group)
Number of subjects: 22
Study: 17536871

Group type: EXPERIMENTAL
Intervention: Tobramycin (300mg/4mL) administered twice daily via nebulizer for 4 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo administered twice daily via nebulizer for 4 weeks
Number of subjects: 59
Study: 14973517

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/nitrendipine 20 mg (E/N)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Losartan 50 mg/hydrochlorothiazide 12.5 mg (L/H)
Number of subjects: 97
Study: 11677518

Group type: EXPERIMENTAL
Intervention: SUPPORT intervention (delivered by 17 nurses)
Number of subjects: 10000
Study: 9599104

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 3232
Study: 8273796

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole (0.5g tid) and tobramycin (4 mg/kg tid)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 2596737

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1,500,000 IU streptokinase
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine anticoagulant therapy (Control)
Number of subjects: 40
Study: 1093634

Group type: EXPERIMENTAL
Intervention: Proflavine photoinactivation
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.5 per cent. idoxuridine ointment (IDU)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 36
Study: 30852657

Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified foods (yoghurt, cheese, eggs, crisp bread) providing 20 µg vitamin D3/day
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 143
Study: 29090352

Group type: EXPERIMENTAL
Intervention: Lower ORP values at 12 h post-CPB
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Lower ORP values at 6 h post-CPB
Number of subjects: 162
Study: 27773378

Group type: EXPERIMENTAL
Intervention: Checklist group (self-administered checklist and paper feedback)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (paper feedback only)
Number of subjects: 20
Study: 23638904

Group type: EXPERIMENTAL
Intervention: Low glycaemic index (LGI) diet, n=33
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional high-fibre diet (HF), n=25
Number of subjects: 58
Study: 23207891

Group type: EXPERIMENTAL
Intervention: 12-week proprioception training program
Number of subjects: 44
Study: 21066883

Group type: EXPERIMENTAL
Intervention: Manipulated acupuncture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-manipulated acupuncture
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Treatment group (manipulated acupuncture)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 50
Study: 18853583

Group type: EXPERIMENTAL
Intervention: 2% lignocaine with adrenaline and fentanyl (LAF)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: LAF, 0.75% ropivacaine, 0.5% levobupivacaine
Number of subjects: 90
Study: 16902063

Group type: EXPERIMENTAL
Intervention: High-fiber, low-fat diet with daily aerobic exercise for 3 weeks
Number of subjects: 22
Study: 12926747

Group type: EXPERIMENTAL
Intervention: Elders with high dental status
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Elders with middle dental status
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Elders with low dental status
Number of subjects: 29

Group type: COMPARATOR
Intervention: Young adults (control group)
Number of subjects: 29
Study: 11778207

Group type: EXPERIMENTAL
Intervention: Early extubation followed by non-invasive mechanical ventilation (MV) via facial mask in 11 cases (study group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Continuous invasive MV in 11 cases (control group)
Number of subjects: 22
Study: 8733148

Group type: EXPERIMENTAL
Intervention: Affine transformation applied to one of two identical patterns in a 'same' trial.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affine transformation applied after the point lying on the diagonal bisector was perturbed in a 'different' trial.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probabilistic model of discrimination performance using qualitative cues.
Number of subjects: 0
Study: 1895677

Group type: EXPERIMENTAL
Intervention: Partial ileal bypass (PIB) surgery
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard medical care (control)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: PIB stone-formers (S)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: PIB non-stone formers (N)
Number of subjects: 146
Study: 6873549

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at a single weekly dose of 15 mg/kg
Number of subjects: 13
Study: 31356221

Group type: EXPERIMENTAL
Intervention: Smartphone-based head-mounted display (HMD) for vestibular rehabilitation
Number of subjects: 30
Study: 29532054

Group type: EXPERIMENTAL
Intervention: mPATH‐CRC (digital health intervention using an iPad application)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: mPATH‐CRC
Number of subjects: 450
Study: 28247026

Group type: COMPARATOR
Intervention: Normal night of sleep (CON, 7.56±0.63 h)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Half of usual time in bed (DEP, 3.83±0.33 h)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DEP condition
Number of subjects: 16

Group type: COMPARATOR
Intervention: CON condition
Number of subjects: 16
Study: 26297203

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing 52-mg IUD (LNG-IUD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Copper T380A IUD (Cu-IUD)
Number of subjects: 32
Study: 23972263

Group type: EXPERIMENTAL
Intervention: Octreotide-LAR (20 mg intramuscular injections every 28 days for 3 years)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution every 28 days for 3 years)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Octreotide-LAR
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 21038631

Group type: EXPERIMENTAL
Intervention: Bunnell suture with reinforcement by a graft of the fascia lata
Number of subjects: 43

Group type: COMPARATOR
Intervention: Simple end-to-end Bunnell suture
Number of subjects: 43
Study: 19120513

Group type: EXPERIMENTAL
Intervention: Naftopidil 50 mg daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg once daily
Number of subjects: 59
Study: 16730924

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 14567252

Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cefdinir (CFDN)
Number of subjects: 65
Study: 10963930

Group type: EXPERIMENTAL
Intervention: Individually focused cognitive-behavioral treatment
Number of subjects: 149

Group type: COMPARATOR
Intervention: Relationship-focused community reinforcement approach
Number of subjects: 149
Study: 9011971

Group type: EXPERIMENTAL
Intervention: Buffer solution
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 502
Study: 8214269

Group type: EXPERIMENTAL
Intervention: 1% niclosamide lotion applied daily for five months
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo lotion applied daily for five months
Number of subjects: 186
Study: 3323611

Group type: EXPERIMENTAL
Intervention: Higher BCKA content supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower BCKA content supplement
Number of subjects: 0
Study: 30562772

Group type: EXPERIMENTAL
Intervention: Tibet plateau group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Plain group
Number of subjects: 70
Study: 26806956

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane-remifentanil
Number of subjects: 50
Study: 24253234

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa/entacapone (LCE)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Levodopa/carbidopa (LC)
Number of subjects: 95
Study: 24589538

Group type: EXPERIMENTAL
Intervention: Plasma-Lyte A
Number of subjects: 46

Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cost-minimization analysis
Number of subjects: 46
Study: 22910317

Group type: EXPERIMENTAL
Intervention: Vatalanib (PTK787/ZK222584)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 20041430

Group type: EXPERIMENTAL
Intervention: Geriaforce tincture
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ginkgo fresh plant extract tablets
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: EGb 761 tablets
Number of subjects: 3
Study: 18001672

Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a plus ribavirin
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2b plus ribavirin
Number of subjects: 208
Study: 16138418

Group type: EXPERIMENTAL
Intervention: Acetate dialysate
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bicarbonate dialysate
Number of subjects: 41
Study: 11873071

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interleukin-2 (rIL-2) 4.5 MIU
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interleukin-2 (rIL-2) 7.5 MIU
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interleukin-2 (rIL-2)
Number of subjects: 511

Group type: COMPARATOR
Intervention: No rIL-2 (Control)
Number of subjects: 511
Study: 10190407

Group type: EXPERIMENTAL
Intervention: Active pacing
Number of subjects: 81

Group type: COMPARATOR
Intervention: Inactive pacing
Number of subjects: 81
Study: 8871752

Group type: EXPERIMENTAL
Intervention: Weekly Epoetin alfa regimen (600 IU/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily Epoetin alfa regimen (300 IU/kg)
Number of subjects: 0
Study: 1624722

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 6705479

Group type: EXPERIMENTAL
Intervention: 99mTc aerosol particles
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 81mKr gas
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aerosol deposition abnormalities
Number of subjects: 20
Study: 31537332

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 308

Group type: COMPARATOR
Intervention: ICD
Number of subjects: 308
Study: 28806275

Group type: COMPARATOR
Intervention: Placebo + Carbohydrate Loading (PLA + LOAD)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Creatine + Moderate Carbohydrate (CR + MOD)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Creatine + Carbohydrate Loading (CR + LOAD)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Creatine (CR)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glycogen Depletion
Number of subjects: 18
Study: 27841974

Group type: EXPERIMENTAL
Intervention: Three needle acupuncture (TNA)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SNA plus manual stimulation (SNA+MS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Single needle acupuncture (SNA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 58
Study: 25072098

Group type: EXPERIMENTAL
Intervention: Exhaled carbon monoxide (CO) measurement
Number of subjects: 1768

Group type: EXPERIMENTAL
Intervention: Exhaled carbon monoxide (CO) measurement after adjusting for smoking behavior
Number of subjects: 1768

Group type: COMPARATOR
Intervention: Cigarettes smoked per day
Number of subjects: 1768
Study: 23152839

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg weekly subcutaneous injections (n = 39)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Mipomersen
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 20212297

Group type: EXPERIMENTAL
Intervention: PCMH principles (personal physician, physician‐directed team, whole‐person orientation, coordination of care, quality and safety, enhanced access)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Personal physician principle, particularly continuity with the same physician
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Number of visits within 2 years
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Whole‐person orientation principle
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Having a well‐visit within 5 years
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Treatment for chronic diseases
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Referral systems to link patients to community programs for preventive counseling
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Use of clinical decision‐support tools
Number of subjects: 24
Study: 17352962

Group type: EXPERIMENTAL
Intervention: Watermelon juice (780 g/day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Watermelon juice (1560 g/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (0 g watermelon juice)
Number of subjects: 23
Study: 15730171

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol and 1 mg norethisterone acetate
Number of subjects: 47

Group type: COMPARATOR
Intervention: 2 mg estradiol and 5 mg norethindrone
Number of subjects: 47
Study: 11889394

Group type: COMPARATOR
Intervention: Control group (normal sensitivity, intact laryngeal adductor reflex)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Absent LAR group (severe sensory deficits)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (normal sensitivity)
Number of subjects: 122
Study: 9539585

Group type: EXPERIMENTAL
Intervention: Right-sided BronchoCath double-lumen tube (R-DLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Univent tube with bronchial blocker (R-UBB)
Number of subjects: 40
Study: 7840381

Group type: EXPERIMENTAL
Intervention: Laparoscopic Appendectomy with endoscopic linear stapler (LAS)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Laparoscopic Appendectomy with catgut ligatures (LAL)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Open Appendectomy (OA)
Number of subjects: 253
Study: 1470875

Group type: EXPERIMENTAL
Intervention: Rapid expansion (once a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Slow expansion (once a week)
Number of subjects: 30
Study: 6437474

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 31044624

Group type: EXPERIMENTAL
Intervention: Ureteroscopy (URS)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 125
Study: 29569328

Group type: EXPERIMENTAL
Intervention: Contingent group (n=19)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-contingent group (n=20)
Number of subjects: 39
Study: 26337026

Group type: EXPERIMENTAL
Intervention: MDRNSTAT
Number of subjects: 0
Study: 24909481

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 60
Study: 22015616

Group type: EXPERIMENTAL
Intervention: Intracoronary bolus administration of abciximab
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous bolus administration of abciximab
Number of subjects: 16
Study: 20570084

Group type: EXPERIMENTAL
Intervention: United States (5.3% prevalence of alcohol abuse)
Number of subjects: 0

Group type: COMPARATOR
Intervention: South Korea (2.0% prevalence of alcohol abuse)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Korea (5.1% prevalence of alcohol dependence)
Number of subjects: 0

Group type: COMPARATOR
Intervention: United States (4.4% prevalence of alcohol dependence)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Men in both countries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Youngest age groups in both countries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Men, employed or never married individuals in both countries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age factor in the United States and Korea
Number of subjects: 0
Study: 17524574

Group type: EXPERIMENTAL
Intervention: Intensive referral to self-help groups (SHGs)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Standard referral to self-help groups (SHGs)
Number of subjects: 345
Study: 16360543

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2, days 1, 8) plus Docetaxel (75 mg/m2, day 1)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Capecitabine (1250 mg/m2, bid days 1-14) plus Docetaxel
Number of subjects: 305
Study: 12037739

Group type: EXPERIMENTAL
Intervention: Modified intravenous glucose tolerance test (IVGTT)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucose effectiveness (Sg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Insulin sensitivity index (SI)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Insulin secretion (AIR(Glucose))
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fasting insulin
Number of subjects: 6
Study: 10562483

Group type: EXPERIMENTAL
Intervention: Atropine (0.02 mg/kg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (isotonic saline solution)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Atropine (in cardio‐inhibitory form)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (in cardio‐inhibitory form)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Atropine (in vasodepressor form)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (in vasodepressor form)
Number of subjects: 113
Study: 8539548

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1 g/kg body weight per day over 2 consecutive days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Observation (no specific therapy)
Number of subjects: 9
Study: 2096044

Group type: EXPERIMENTAL
Intervention: Stapled anastomosis
Number of subjects: 272

Group type: COMPARATOR
Intervention: Hand sewn anastomosis
Number of subjects: 272
Study: 338254

Group type: EXPERIMENTAL
Intervention: 3 x 20 mg piribedil tablets
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 x 50 mg piribedil in a sustained-release tablet formulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31663972

Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic prostatectomy (RALP)
Number of subjects: 50300
Study: 31343603

Group type: EXPERIMENTAL
Intervention: Cold Water Shower (CWS) - 15 minutes, 15° C water shower
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (SIT25) - 15 minutes passive recovery in 25° C room
Number of subjects: 9
Study: 28217989

Group type: EXPERIMENTAL
Intervention: Endovenous radiofrequency ablation (RFA)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Ultrasound guided foam sclerotherapy (UGFS)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: High ligation and stripping (HL/S)
Number of subjects: 500
Study: 25419615

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg/d
Number of subjects: 7469

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg/d
Number of subjects: 7469

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7469

Group type: COMPARATOR
Intervention: Other disease-modifying treatments
Number of subjects: 7469

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment for relapses
Number of subjects: 7469

Group type: EXPERIMENTAL
Intervention: Postmarketing setting (Fingolimod 0.5 mg/d)
Number of subjects: 7469
Study: 23797054

Group type: EXPERIMENTAL
Intervention: Home blood pressure measurement (HBPM) by a trained relative
Number of subjects: 60
Study: 21784757

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19699855

Group type: EXPERIMENTAL
Intervention: Nurse-administered disease-management intervention combining patient self-management support and provider medication management
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Nurse-administered disease-management intervention
Number of subjects: 400
Study: 16679713

Group type: EXPERIMENTAL
Intervention: Small container
Number of subjects: 20

Group type: COMPARATOR
Intervention: Large container
Number of subjects: 20
Study: 15326133

Group type: EXPERIMENTAL
Intervention: Mean height contour measurements along the disc margin
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Mean height contour measurements in the parapapillary region
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: SVM Gaussian techniques with regional parameters
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: SVM Gaussian techniques with global parameters
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Mean height contour measures along the disc margin
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Mean height contour measures in the parapapillary region
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Cross-validation and optimization techniques
Number of subjects: 230
Study: 11502793

Group type: EXPERIMENTAL
Intervention: Sulfonylurea treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nondiabetic obese women)
Number of subjects: 0